Vasiliki Leventaki, MD
Vasiliki Leventaki, MD

Vasiliki Leventaki, MD

Research Associate, St. Jude Faculty



MD – National and Kapodistrian University of Athens, Athens, Greece
Residency – Anatomic and Clinical, University of Utah
Fellowship – Hematopathology, UT MD Anderson Cancer Center

Research Interests

  • The use of high-resolution genomic methods to identify novel and recurrent genomic aberrations in different types of pediatric lymphoma and their correlation with disease progression and treatment outcome.
  • Investigation of the biological mechanisms by which specific genomic alterations in pediatric lymphomas contribute to tumor development.

Selected Publications

Leventaki V*, Rodic V, Tripp SR, Bayerl MG, Perkins SL, Barnette P, Schiffman JD, Miles RR. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. Br J Haematol 158(6):763-771, 2012. *This work was partially supported by a Resident Research Grant from the College of American Pathologists Foundation.

Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymph 53(9):1839-1841, 2012.

Drakos E, Leventaki V, Atsaves V, Schlette EJ, Lin P, Vega F, Miranda RN, Claret FX, Medeiros LJ, Rassidakis GZ. Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin lymphomas. Hum Pathol 42(8):1117-1124, 2011.

Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene 29(46):6125-6137, 2010.

Chen W, Drakos E, Grammatikakis I, Schlette EJ, Li J, Leventaki V, Staikou-Drakopoulou E, Patsouris E, Panayiotidis P, Medeiros LJ, Rassidakis GZ. mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer 9:292, 2010.

Inamdar KV, Romaguera JE, Drakos E, Knoblock RJ, Garcia M, Leventaki V, Medeiros LJ, Rassidakis GZ. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine. Cancer 115(20):4727-4736, 2009.

Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE. Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer115(23):5481-5489, 2009.

Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ, Rassidakis GZ. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia 23(4):784-790, 2009.

Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 13(11):3380-3387, 2007.

Leventaki V, Drakos E, Lim SM, Elenitoba-Johnson SK, Claret FX, Medeiros LJ, Rassidakis GZ. NPM-ALK oncogenic kinase promotes cell cycle progression through activation of JNK/cJun in anaplastic large cell lymphoma. Blood 110(5):1621-1630, 2007.

Peponi E*, Drakos E*, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mTOR signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 169(6):2171-2180, 2006. *Equal contribution.

Drakos E, Leventaki V, Schlette EJ, Jones D, Lin P, Medeiros LJ, Rassidakis GZ. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders. Am J Surg Pathol 31(3):447-453, 2006.

Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret F-X, Rassidakis GZ. Activation of mTOR Signaling Pathway Contributes to Tumor Cell Survival in ALK+ anaplastic large cell lymphoma. Cancer Res 66(13):6589-6597, 2006.

Oyarzo MP, Medeiros LJ, Atwell C, Feretzaki M, Leventaki V, Wang S, Drakos E, Amin HM, Rassidakis GZ. c-FLIP Confers Resistance to Fas-mediated apoptosis in anaplastic large cell lymphoma. Blood 107(6):2544-2537, 2006.

Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 23(32):5426-5434, 2004.

Amin H, Medeiros LJ, Ma Y, Feretzaki M, Das P, Leventaki V, Rassidakis GZ, O’Connor SL, McDonnell TJ, LaiR. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 22(35):5399-5407, 2003.

Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, McDonnell TJ. Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumors. J Pathol 199(1):84-89, 2003.

Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, Schmitt-Graeff A, Herling M, Amin HM, Lai R. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res 9(10):3692-3699, 2003.

Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL, Keating MJ, Lai R. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 127(4):424-431, 2003.

Last update: August 2013